|1.15 0.09 (8.49%)||12-01 16:00|
|Targets||6-month :||1.5||1-year :||1.76|
|Resists||First :||1.28||Second :||1.5|
|Supports||First :||0.92||Second :||0.76|
|MAs||MA(5) :||1.1||MA(20) :||1.13|
|MA(100) :||1.44||MA(250) :||2.02|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||56.5||D(3) :||51|
|52-week||High :||3.78||Low :||0.92|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LXRX ] has closed below upper band by 21.0%. Bollinger Bands are 62.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||1.16 - 1.17||1.17 - 1.18|
|Low:||1.03 - 1.03||1.03 - 1.04|
|Close:||1.14 - 1.15||1.15 - 1.16|
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||245 (M)|
|Held by Insiders||1.036e+008 (%)|
|Held by Institutions||0.9 (%)|
|Shares Short||20,240 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-30 %|
|Return on Assets (ttm)||636.4 %|
|Return on Equity (ttm)||-41.5 %|
|Qtrly Rev. Growth||530000 %|
|Gross Profit (p.s.)||271.89|
|Sales Per Share||-96|
|Qtrly Earnings Growth||-0.8 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-133 (M)|
|Price to Book value||0|
|Price to Sales||-0.02|
|Price to Cash Flow||2.34|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|